JP2008522972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008522972A5 JP2008522972A5 JP2007544611A JP2007544611A JP2008522972A5 JP 2008522972 A5 JP2008522972 A5 JP 2008522972A5 JP 2007544611 A JP2007544611 A JP 2007544611A JP 2007544611 A JP2007544611 A JP 2007544611A JP 2008522972 A5 JP2008522972 A5 JP 2008522972A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solvent system
- fatty acid
- fenofibrate
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002904 solvent Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 10
- 229960002297 Fenofibrate Drugs 0.000 claims 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims 10
- 239000000194 fatty acid Substances 0.000 claims 10
- -1 fatty acid esters Chemical class 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 3
- 125000003158 alcohol group Chemical group 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000562 conjugate Substances 0.000 claims 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 102000014961 Protein Precursors Human genes 0.000 claims 1
- 108010078762 Protein Precursors Proteins 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Claims (13)
- フェノフィブラートと、脂肪酸エステルを含む溶媒系とを含む単位剤型における医薬組成物であって、前記脂肪酸エステルの酸又はアルコール部分が、Ｃ１〜Ｃ１５基を含み、前記フェノフィブラートが、前記溶媒系に実質的に溶解された医薬組成物。
- 前記脂肪酸エステルの酸又はアルコール部分が、Ｃ１〜Ｃ６基を含む、請求項１記載の医薬組成物。
- 前記脂肪酸エステルの酸又はアルコール部分が、Ｃ１〜Ｃ４基を含む、請求項１記載の医薬組成物。
- フェノフィブラートと、ω−５、ω−６、ω−７、ω−９脂肪酸エステル若しくはその薬理学的に許容できる誘導体、接合体、前駆体もしくは塩、又はそれらの混合物を含む溶媒系とを含み、前記フェノフィブラートが、前記溶媒系に実質的に溶解された、単位剤型における医薬組成物。
- フェノフィブラートと、ステノール脂肪酸エステル又はスタノール脂肪酸エステル若しくはその薬理学的に許容できる誘導体、接合体、前駆体もしくは塩、又はそれらの混合物を含む溶媒系とを含み、前記フェノフィブラートが、前記溶媒系に実質的に溶解された、単位剤型における医薬組成物。
- 前記フェノフィブラートが、前記溶媒系に実質的に完全に溶解された、請求項１から５のいずれか１項記載の医薬組成物。
- 室温で６ヵ月以上安定である、請求項１から５のいずれか１項記載の医薬組成物。
- 前記溶媒系が、前記溶媒系の総重量に対して５０％ｗ／ｗ未満の前記脂肪酸エステル以外の少なくとも１種類の可溶化剤を含有する、請求項１から５のいずれか１項記載の医薬組成物。
- 前記溶媒系が、脂肪酸エステルからなる、請求項１から５のいずれか１項記載の医薬組成物。
- 前記溶媒系が、脂肪酸エステル以外の少なくとも１種類の可溶化剤を更に含み、脂肪酸エステル対前記可溶化剤の重量比が少なくとも０．５対１である、請求項１から５のいずれか１項記載の医薬組成物。
- 前記溶媒系が、前記溶媒系の総重量に対して２０％ｗ／ｗ未満の少なくとも１種類の親水溶媒を含有する、請求項１から５のいずれか１項記載の医薬組成物。
- 前記フェノフィブラートが、微粒化していない、或いは他の機械技術に曝されていない結晶性フェノフィブラートである、請求項１から５のいずれか１項記載の医薬組成物。
- 前記フェノフィブラートの平均粒径が、２５μｍ以上である、請求項１から５のいずれか１項記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63312604P | 2004-12-06 | 2004-12-06 | |
| PCT/US2005/044036 WO2006062933A2 (en) | 2004-12-06 | 2005-12-05 | Stable compositions of fenofibrate with fatty acid esters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008522972A JP2008522972A (ja) | 2008-07-03 |
| JP2008522972A5 true JP2008522972A5 (ja) | 2009-01-22 |
Family
ID=36578470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544611A Pending JP2008522972A (ja) | 2004-12-06 | 2005-12-05 | 脂肪酸エステルを有する安定性フェノフィブラート組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060188529A1 (ja) |
| EP (1) | EP1830804A2 (ja) |
| JP (1) | JP2008522972A (ja) |
| KR (1) | KR20070098855A (ja) |
| CN (1) | CN101094647A (ja) |
| AU (1) | AU2005314197A1 (ja) |
| BR (1) | BRPI0518426A2 (ja) |
| CA (1) | CA2589656A1 (ja) |
| EA (1) | EA200701228A1 (ja) |
| MX (1) | MX2007006775A (ja) |
| NO (1) | NO20073457L (ja) |
| WO (1) | WO2006062933A2 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008516890A (ja) * | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| CN102307576A (zh) | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| NZ594236A (en) * | 2009-01-26 | 2014-08-29 | Univ Taipei Medical | Use of pterosin compounds for treating diabetes and obesity |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| AU2013277441B2 (en) | 2012-06-17 | 2017-07-06 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| DE69842121D1 (de) * | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
| US6814977B1 (en) * | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US7014864B1 (en) * | 1998-12-18 | 2006-03-21 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| CA2355820A1 (en) * | 1998-12-18 | 2000-06-29 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| WO2000057918A2 (en) * | 1999-03-31 | 2000-10-05 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
| US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
-
2005
- 2005-12-05 KR KR1020077015607A patent/KR20070098855A/ko not_active Application Discontinuation
- 2005-12-05 BR BRPI0518426-6A patent/BRPI0518426A2/pt not_active IP Right Cessation
- 2005-12-05 EA EA200701228A patent/EA200701228A1/ru unknown
- 2005-12-05 US US11/293,496 patent/US20060188529A1/en not_active Abandoned
- 2005-12-05 CA CA002589656A patent/CA2589656A1/en not_active Abandoned
- 2005-12-05 CN CNA2005800454249A patent/CN101094647A/zh active Pending
- 2005-12-05 MX MX2007006775A patent/MX2007006775A/es unknown
- 2005-12-05 EP EP05849159A patent/EP1830804A2/en not_active Withdrawn
- 2005-12-05 WO PCT/US2005/044036 patent/WO2006062933A2/en active Search and Examination
- 2005-12-05 AU AU2005314197A patent/AU2005314197A1/en not_active Abandoned
- 2005-12-05 JP JP2007544611A patent/JP2008522972A/ja active Pending
-
2007
- 2007-07-04 NO NO20073457A patent/NO20073457L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008522972A5 (ja) | ||
| US10238612B2 (en) | Transdermal administration of tamsulosin | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2008540394A5 (ja) | ||
| RU2019144960A (ru) | Мультибиотические средства и способы их применения | |
| JP2007516297A5 (ja) | ||
| IL265774A (en) | Diagnosis, prevention and treatment of joint diseases | |
| JP2010077141A5 (ja) | ||
| NZ596386A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| HRP20151051T1 (hr) | Formulacije src/abl inhibitora | |
| US20160095928A1 (en) | Composition for hot melt extrusion and method for producing hot melt extrudate by using same | |
| WO2009050738A3 (en) | An orally administerable solid pharmaceutical composition and a process thereof | |
| JP2007506774A5 (ja) | ||
| JP2007509981A5 (ja) | ||
| JPH06305958A (ja) | 消炎鎮痛外用貼付剤 | |
| JP2009530398A5 (ja) | ||
| JP2012530719A5 (ja) | ||
| ES2541141T3 (es) | Composición farmacéutica para el tratamiento de las enfermedades del hígado graso | |
| JP2011507838A5 (ja) | ||
| JP2003508484A5 (ja) | ||
| CA2742645A1 (en) | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester | |
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| DE602006000819D1 (de) | Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung | |
| JP2002520281A5 (ja) | ||
| JP2010510194A5 (ja) |